H. Stein, D. Y. Mason, J. Gerdes, N. O'connor, J. Wainscoat et al., The expression of the
URL : https://hal.archives-ouvertes.fr/hal-02546620

, Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells, Blood. oct, vol.66, issue.4, pp.848-58, 1985.

N. Tsuyama, K. Sakamoto, S. Sakata, A. Dobashi, and K. Takeuchi, Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects, J Clin Exp Hematop JCEH, vol.57, issue.3, pp.120-162, 2017.

G. Hapgood and K. J. Savage, The biology and management of systemic anaplastic large cell lymphoma, Blood. 2 juill, vol.126, issue.1, pp.17-25, 2015.

A. Weilemann, M. Grau, T. Erdmann, O. Merkel, U. Sobhiafshar et al., Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma, Blood. 1 janv, vol.125, issue.1, pp.124-156, 2015.

C. Villalva, F. Bougrine, G. Delsol, and P. Brousset, Bcl-2 expression in anaplastic large cell lymphoma, Am J Pathol. mai, vol.158, issue.5, pp.1889-90, 2001.

G. Delsol, L. Brugières, P. Gaulard, E. Espinos, and L. Lamant, Anaplastic large cell lymphoma, ALKpositive and anaplastic large cell lymphoma ALK-negative, Hematol Meet Rep Former Haematol Rep, p.17, 2009.

, Disponible sur

M. Boi, E. Zucca, G. Inghirami, and F. Bertoni, Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas, Br J Haematol. 1 mars, vol.168, issue.6, pp.771-83, 2015.

E. Campo, S. H. Swerdlow, N. L. Harris, S. Pileri, H. Stein et al., The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood. 12 mai, vol.117, pp.5019-5051, 2011.

N. L. Harris, E. S. Jaffe, H. Stein, P. M. Banks, J. K. Chan et al., A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group, Blood. 1 sept, vol.84, issue.5, pp.1361-92, 1994.

R. L. Ten-berge, P. C. De-bruin, J. J. Oudejans, G. J. Ossenkoppele, P. Van-der-valk et al., ALKnegative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology, vol.43, pp.462-471, 2003.

S. H. Swerdlow, E. Campo, S. A. Pileri, N. L. Harris, H. Stein et al., The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.19, issue.20, pp.2375-90, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

C. Laurent, A. Delas, P. Gaulard, C. Haioun, A. Moreau et al., Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes, Ann Oncol Off J Eur Soc Med Oncol. févr, vol.27, issue.2, pp.306-320, 2016.

A. N. Leberfinger, B. J. Behar, N. C. Williams, K. L. Rakszawski, J. D. Potochny et al., Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review, JAMA Surg. 1 déc, vol.152, issue.12, pp.1161-1169, 2017.

J. A. Keech and B. J. Creech, Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant

, Plast Reconstr Surg. août, vol.100, issue.2, pp.554-559, 1997.

R. Willemze, L. Cerroni, W. Kempf, B. E. Facchetti, F. Swerdlow et al., The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas, Blood. 11 janv, 2019.

Y. H. Kim, R. Willemze, N. Pimpinelli, S. Whittaker, E. A. Olsen et al., TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC), Blood. 15 juill, vol.110, issue.2, pp.479-84, 2007.

K. Agrawal, T. Shet, E. Sridhar, S. Dhende, M. Sengar et al., Story of survival in anaplastic large cell lymphoma -sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases, Indian J Pathol Microbiol. déc, vol.60, issue.4, pp.2683-93, 2013.

D. Sibon, M. Fournier, J. Brière, L. Lamant, C. Haioun et al., Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, issue.32, pp.3939-3985, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00766851

S. H. Swerdlow, E. Campo, N. L. Harris, E. S. Jaffe, S. A. Pileri et al., WHO classification of tumours of haematopoietic and lymphoid tissues, éditeurs, vol.585, 2017.

D. Benharroch, Z. Meguerian-bedoyan, L. Lamant, C. Amin, L. Brugières et al.,

, ALK-positive lymphoma: a single disease with a broad spectrum of morphology, Blood. 15 mars, vol.91, issue.6, pp.2076-84, 1998.

A. Shustov and L. Soma, Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management, Cancer Treat Res, vol.176, pp.127-171, 2019.

R. L. King, L. N. Dao, E. D. Mcphail, E. S. Jaffe, J. Said et al., Morphologic Features of ALKnegative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements, Am J Surg Pathol. janv, vol.40, issue.1, pp.36-43, 2016.

P. Blombery, E. R. Thompson, K. Jones, G. M. Arnau, S. Lade et al., Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma, Haematologica, vol.101, issue.9, pp.387-390, 2016.

G. Hu, S. Dasari, Y. Asmann, P. Greipp, R. Knudson et al., Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma, Leukemia. févr, vol.32, issue.2, pp.565-574, 2018.

R. C. Lynch, D. Gratzinger, and R. H. Advani, Clinical Impact of the 2016 Update to the WHO Lymphoma Classification, Curr Treat Options Oncol. juill, vol.18, issue.7, p.45, 2017.

P. Gaulard and L. De-leval, ALK-negative anaplastic large-cell lymphoma, Blood. 14 janv, vol.127, issue.2, pp.175-182, 2016.

J. Taylor, W. Xiao, A. , and O. , Diagnosis and classification of hematologic malignancies on the basis of genetics, Blood, vol.27, issue.4, pp.410-433, 2017.

V. Atsaves, N. Tsesmetzis, D. Chioureas, L. Kis, V. Leventaki et al., PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma, Leukemia, vol.31, issue.7, pp.1633-1640, 2017.

C. Bandini, A. Pupuleku, E. Spaccarotella, E. Pellegrino, R. Wang et al., IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas, Cancers. 18 janv, vol.10, issue.1, 2018.

J. J. Han, M. O'byrne, M. J. Stenson, M. J. Maurer, L. E. Wellik et al., Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma, Blood Cancer J. 12 nov, vol.8, issue.11, p.110, 2018.

P. Castellar, E. R. Jaffe, E. S. Said, J. W. Swerdlow, S. H. Ketterling et al., ALKnegative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes, Blood. 28 août, vol.124, issue.9, pp.1473-80, 2014.

M. B. Pedersen, S. J. Hamilton-dutoit, K. Bendix, R. P. Ketterling, P. P. Bedroske et al., DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study, Blood, vol.27, issue.4, pp.554-561, 2017.

A. L. Feldman, A. Dogan, D. I. Smith, M. E. Law, S. M. Ansell et al., Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing, Blood. 20 janv, vol.117, issue.3, pp.915-924, 2011.

A. L. Feldman, M. Law, E. D. Remstein, W. R. Macon, L. A. Erickson et al., Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas, Leukemia. mars, vol.23, issue.3, pp.574-80, 2009.

R. N. Chavan, A. G. Bridges, R. A. Knudson, R. P. Ketterling, N. Comfere et al., Somatic rearrangement of the TP63 gene preceding development of mycosis fungoides with aggressive clinical course, Blood Cancer J, vol.4, p.253, 2014.

M. H. Heo, H. Y. Park, Y. H. Ko, W. S. Kim, and S. J. Kim, IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma, J Cancer, vol.8, issue.6, pp.1018-1042, 2017.

X. Liang, B. Branchford, B. Greffe, L. Mcgavran, B. Carstens et al., Dual ALK and MYC rearrangements leading to an aggressive variant of anaplastic large cell lymphoma, J Pediatr Hematol Oncol. juill, vol.35, issue.5, pp.209-213, 2013.

G. Z. Rassidakis, A. Thomaides, S. Wang, Y. Jiang, A. Fourtouna et al., p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma, Leukemia. sept, vol.19, issue.9, pp.1663-1672, 2005.

H. L. Li, X. P. Huang, X. H. Zhou, T. H. Ji, Z. Q. Wu et al., Correlation of seven biological factors (Hsp90a, p53, MDM2, Bcl-2, Bax, Cytochrome C, and Cleaved caspase3) with clinical outcomes of ALK+ anaplastic large-cell lymphoma, Biomed Environ Sci BES. déc, vol.24, issue.6, pp.630-671, 2011.

J. T. Jung, D. H. Kim, E. K. Kwak, J. G. Kim, T. I. Park et al., Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas, Ann Hematol. sept, vol.85, issue.9, pp.575-81, 2006.

T. Shukuya and D. P. Carbone, Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.11, issue.7, pp.976-88, 2016.

M. Shi, M. Roemer, B. Chapuy, X. Liao, H. Sun et al., Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain, Am J Surg Pathol. déc, vol.38, issue.12, pp.1715-1738, 2014.

M. Four, V. Cacheux, A. Tempier, D. Platero, M. Fabbro et al., PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival, Hematol Oncol. déc, vol.35, issue.4, pp.487-96, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01794739

S. Menguy, M. Prochazkova-carlotti, M. Beylot-barry, F. Saltel, B. Vergier et al., PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Am J Surg Pathol. mars, vol.42, issue.3, pp.326-360, 2018.

C. Mitteldorf, A. Berisha, M. C. Pfaltz, S. Broekaert, M. P. Schön et al., Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets, Am J Surg Pathol. juill, vol.41, issue.7, pp.998-1004, 2017.

A. Hayano, Y. Komohara, Y. Takashima, H. Takeya, J. Homma et al., Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study, Anticancer Res, vol.37, issue.10, pp.5655-66, 2017.

D. Twa, F. C. Chan, S. Ben-neriah, B. W. Woolcock, A. Mottok et al., Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma, Blood. 27 mars, vol.123, issue.13, pp.2062-2067, 2014.

D. Twa, A. Mottok, F. C. Chan, S. Ben-neriah, B. W. Woolcock et al., Recurrent genomic rearrangements in primary testicular lymphoma, J Pathol. juin, vol.236, issue.2, pp.136-177, 2015.

B. Chapuy, M. Roemer, C. Stewart, Y. Tan, R. P. Abo et al., Targetable genetic features of primary testicular and primary central nervous system lymphomas, Blood. 18 févr, vol.127, issue.7, pp.869-81, 2016.

K. Georgiou, L. Chen, M. Berglund, W. Ren, N. De-miranda et al., Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas, Blood, vol.16, issue.24, pp.3026-3060, 2016.

K. Kataoka, Y. Shiraishi, Y. Takeda, S. Sakata, M. Matsumoto et al., Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers, Nature, vol.16, issue.7607, pp.402-408, 2016.

H. Horlad, C. Ma, H. Yano, C. Pan, K. Ohnishi et al., An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma, Cancer Sci, vol.107, issue.11, pp.1696-704, 2016.

C. Ma, H. Horlad, C. Pan, H. Yano, K. Ohnishi et al., Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines, J Clin Exp Hematop JCEH. 5 juill, vol.57, issue.1, pp.21-26, 2017.

K. J. Savage, N. L. Harris, J. M. Vose, F. Ullrich, E. S. Jaffe et al., ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project, Blood. 15 juin, vol.111, issue.12, pp.5496-504, 2008.

A. Gallamini, C. Stelitano, R. Calvi, M. Bellei, D. Mattei et al., Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study, Blood. 1 avr, vol.103, issue.7, pp.2474-2483, 2004.

R. Doghri, L. B. Hadjkacem, Y. Houcine, L. Charfi, M. Driss et al., Prognostic factors of ALKnegative anaplastic large-cell lymphoma: a single-institution experience, Ann Hematol. avr, vol.97, issue.4, pp.725-731, 2018.

M. R. Hassler, W. Pulverer, R. Lakshminarasimhan, E. Redl, J. Hacker et al., Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling, Cell Rep, vol.04, issue.2, pp.596-608, 2016.

I. Scarfò, E. Pellegrino, E. Mereu, I. Kwee, L. Agnelli et al., Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts, Blood. 14 janv, vol.127, issue.2, pp.221-253, 2016.

L. Agnelli, E. Mereu, E. Pellegrino, T. Limongi, I. Kwee et al., Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma, Blood. 9 août, vol.120, issue.6, pp.1274-81, 2012.

L. Nikolaenko, J. Zain, S. T. Rosen, and C. Querfeld, CD30-Positive Lymphoproliferative Disorders, Cancer Treat Res, vol.176, pp.249-68, 2019.

A. Phan, R. Veldman, and M. J. Lechowicz, T-cell Lymphoma Epidemiology: the Known and Unknown

, Curr Hematol Malig Rep, vol.11, issue.6, pp.492-503, 2016.

J. M. Martin, H. Wu, and S. K. Barta, CD30+ T-cell lymphoproliferative disorders, Chin Clin Oncol, 2018.

D. A. Wada, M. E. Law, E. D. Hsi, D. J. Dicaudo, L. Ma et al., Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies, Mod Pathol Off J U S Can Acad Pathol Inc. avr, vol.24, issue.4, pp.596-605, 2011.

A. Pham-ledard, M. Prochazkova-carlotti, E. Laharanne, B. Vergier, T. Jouary et al.,

, IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases, J Invest Dermatol. mars, vol.130, issue.3, pp.816-841, 2010.

L. Prieto-torres, S. M. Rodriguez-pinilla, A. Onaindia, M. Ara, L. Requena et al., Molecular alterations in primary cutaneous CD30 lymphoproliferative disorders, Haematologica. 10 janv, 2019.

M. W. Bekkenk, F. A. Geelen, P. C. Van-voorst-vader, F. Heule, M. L. Geerts et al., Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment, Blood. 15 juin, vol.95, issue.12, pp.3653-61, 2000.

N. Booken, S. Goerdt, and C. Klemke, Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry, J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. mai, vol.10, issue.5, pp.331-340, 2012.

C. A. Gidengil, Z. Predmore, S. Mattke, K. Van-busum, and B. Kim, Breast implant-associated anaplastic large cell lymphoma: a systematic review, Plast Reconstr Surg. mars, vol.135, issue.3, pp.713-733, 2015.

R. N. Miranda, T. N. Aladily, H. M. Prince, R. Kanagal-shamanna, D. De-jong et al., Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients, J Clin Oncol Off J Am Soc Clin Oncol. 10 janv, vol.32, issue.2, pp.114-134, 2014.

P. Blombery, E. Thompson, G. L. Ryland, R. Joyce, D. J. Byrne et al., Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma, Oncotarget, vol.9, issue.90, pp.36126-36162, 2018.

T. N. Aladily, L. J. Medeiros, K. Alayed, and R. N. Miranda, Breast implant-associated anaplastic large cell lymphoma: a newly recognized entity that needs further refinement of its definition, Leuk Lymphoma. avr, vol.53, issue.4, pp.749-50, 2012.

S. Horwitz, O. A. O'connor, B. Pro, T. Illidge, M. Fanale et al., Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial, Lancet Lond Engl. 19 janv, vol.393, pp.229-269, 2019.

J. Chen, Y. Zhang, M. N. Petrus, W. Xiao, A. Nicolae et al., Cytokine receptor signaling is required for the survival of ALK-anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations, Proc Natl Acad Sci, vol.114, issue.15, pp.3975-80, 2017.

N. Prutsch, E. Gurnhofer, T. Suske, H. C. Liang, M. Schlederer et al., Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma, Leukemia. 21 août, 2018.

N. A. Johnson, G. W. Slack, K. J. Savage, J. M. Connors, S. Ben-neriah et al., Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, issue.28, pp.3452-3461, 2012.

T. M. Green, K. H. Young, C. Visco, Z. Y. Xu-monette, A. Orazi et al., Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, issue.28, pp.3460-3467, 2012.

W. Zhang, Z. Wang, Y. Luo, D. Zhong, Y. Luo et al., GATA3 expression correlates with poor prognosis and tumor-associated macrophage infiltration in peripheral T cell lymphoma, Oncotarget, vol.7, issue.40, pp.65284-94, 2016.

X. Wang, R. L. Boddicker, S. Dasari, J. S. Sidhu, M. E. Kadin et al., Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping, Hum Pathol, vol.64, pp.19-27, 2017.

A. Zhang, K. Ohshima, K. Sato, M. Kanda, J. Suzumiya et al., Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas, Pathol Int. déc, vol.49, issue.12, pp.1043-52, 1999.

A. Chatzitolios, I. Venizelos, G. Tripsiannis, G. Anastassopoulos, and N. Papadopoulos, Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma, Ann Hematol. sept, vol.89, issue.9, pp.889-96, 2010.

C. Krishnan, R. A. Warnke, D. A. Arber, Y. Natkunam, J. Van-dongen et al., PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis, Am J Surg Pathol. févr, vol.34, issue.2, pp.178-89, 2010.

, Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and Tcell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936, Leukemia. déc, vol.17, issue.12, pp.2257-317, 2003.

J. D. Khoury, L. J. Medeiros, G. Z. Rassidakis, M. A. Yared, P. Tsioli et al., Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK-anaplastic large cell lymphoma, Clin Cancer Res Off J Am Assoc Cancer Res. 1 sept, vol.9, issue.10, pp.3692-3701, 2003.

T. N. Aladily, L. J. Medeiros, M. B. Amin, N. Haideri, D. Ye et al., Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases, Am J Surg Pathol. juill, vol.36, issue.7, pp.1000-1008, 2012.

P. L. Zinzani, C. Pellegrini, A. Broccoli, V. Stefoni, L. Gandolfi et al., Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified, Leuk Lymphoma. août, vol.52, issue.8, pp.1585-1593, 2011.

F. Morschhauser, O. Fitoussi, C. Haioun, C. Thieblemont, H. Quach et al., A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial, Eur J Cancer Oxf Engl, vol.49, issue.13, pp.2869-76, 1990.

R. Crescenzo, F. Abate, E. Lasorsa, &. Tabbo, M. Gaudiano et al., Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma, Cancer Cell. 13 avr, vol.27, issue.4, pp.516-548, 2015.

J. Iqbal, G. Wright, C. Wang, A. Rosenwald, R. D. Gascoyne et al., Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma, Blood. 8 mai, vol.123, pp.2915-2938, 2014.

S. Monaco, L. Tsao, V. V. Murty, S. V. Nandula, V. Donovan et al., Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c-myc rearrangement terminating in a leukemic phase, Am J Hematol. janv, vol.82, issue.1, pp.59-64, 2007.

H. Huang, C. Liao, T. Liu, H. You, M. Wang et al., TP53 mutations in peripheral mature T and NK cell lymphomas: a whole-exome sequencing study with correlation to p53 expression, Hum Pathol. oct, vol.80, pp.145-51, 2018.

M. Gallo, V. Cacheux, L. Vincent, C. Bret, A. Tempier et al., Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14, Virchows Arch Int J Pathol. déc, vol.469, issue.6, pp.697-706, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01824583

A. Stengel, W. Kern, T. Haferlach, M. Meggendorfer, A. Fasan et al., The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases, Leukemia, vol.31, issue.3, pp.705-716, 2017.

L. Stefancikova, M. Moulis, P. Fabian, I. Vasova, F. Zedek et al., Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma, Int J Oncol. déc, vol.39, issue.6, pp.1413-1433, 2011.

J. Kiyasu, H. Miyoshi, A. Hirata, F. Arakawa, A. Ichikawa et al., Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma, Blood, vol.126, pp.2193-201, 2015.

W. Xing, K. Dresser, R. Zhang, A. M. Evens, H. Yu et al., PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications, Oncotarget. 13 sept, vol.7, issue.37, pp.59976-86, 2016.

. Netgen, Prise en charge du lymphome B diffus à grandes cellules en, 2012.

, Table1 -données cliniques et histopathologiques Clinique ALCL ALK-N=37 sALCL ALK-n=22 cALCL n=13 BiALCL n=2